Tag - Emovi

Emovi, Inc. Partners with Laurent Duvernay-Tardif, Kansas City Chiefs’ Right Guard and McGill Medical School Graduate

Ziad2022-11-25T14:03:25-05:00 Emovi, Inc. signed a multiyear endorsement agreement with Kansas City Chiefs guard Laurent Duvernay-Tardif, MDCM to help support knowledge transfer to healthcare professionals and patients about Knee Kinesiography with KneeKG™. Read more >>

Emovi Announces Results of Clinical Trial to Manage Knee Osteoarthritis with KneeKGTM

Ziad2022-11-25T14:03:26-05:00 Today, Emovi, Inc. announces positive results from a randomized, controlled trial involving KneeKG™, Emovi’s flagship medical device and the first device that enables healthcare professionals to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. Read more >>

Emovi, Inc. Receives $4.8 Million in Financial Assistance from Quebec Government to Support Expansion in the United States

Ziad2022-11-25T14:03:26-05:00 Emovi, Inc. announced today they have received the support of the Quebec government with financial assistance of $4.8 million bringing their total funding for 2019 over $20 million. The investment is part of the BioMed Propulsion program administered by Investissement Québec and will be used to expand Emovi’s KneeKG into the US market. Read more >>

Canadian Olympian gold medal Bruny Surin Assessed by KneeKG, Becomes Brand Ambassador

Ziad2022-11-25T14:03:26-05:00 Emovi, Inc. today announced that Canadian Olympian Bruny Surin, a KneeKG™ patient, has joined as an official Brand Ambassador and spokesperson for KneeKG, the first in-clinic device that meets the global need for measuring knee function with objective and quantifiable data associated with mechanical knee markers and functional deficiencies. Read more >>

Emovi CSO Dr. Alexandre Fuentes Presents “Functional Return to Duty Decision Making Post MTBI and Musculoskeletal Injury” During 2019 MHSRS

Ziad2022-11-25T14:03:27-05:00 Emovi, Inc., manufacturer of the KneeKG device, today announced that Chief Science Officer, Dr. Alexandre Fuentes will present at the Military Health System Research Symposium (MHSRS), which takes place Aug 19-21, 2019 in Kissimmee, Florida. Read more >>

New Device Pinpoints Knee Pain Sources Better in Minutes

Ziad2022-11-25T14:03:27-05:00 Montreal, Canada-based Emovi, Inc. has announced the U.S. launch of KneeKG, the first in-clinic device that enables physicians to assess knees “while the patient is in motion and weight-bearing.” Read more >>

An EKG for the Knee

Ziad2022-11-25T14:03:27-05:00 Knee pain due to arthritis or injury is the second most common cause of chronic pain in the United States. Osteoarthritis affects more than 30 million adults in the United States. And the rate of anterior cruciate ligament (ACL) tears among children and teens has been increasing about 2.3% per year for the past two decades, according to a new study. Read more >>

Emovi Announces U.S. Commercial Launch of KneeKG In-Clinic Device that Measures and Quantifies Knee Function

Ziad2022-11-25T14:03:37-05:00 Emovi, Inc. today announced the U.S. launch of KneeKG™, the first in-clinic device that meets the global need for measuring knee function with objective and quantifiable data associated with mechanical knee markers and functional deficiencies. Read more >>

Emovi is Accelerating its Growth Through a 15M$ Series C Investment Led by TVM Capital Life Science

Ziad2022-11-25T14:03:38-05:00 Emovi announced today its partnership with TVM Capital Life Science and co-investors StandUp Ventures and Desjardins Capital to support its global commercial activities. This 15M$ Series C investment is combined with other capital for a total of 20M$. Read more >>

Emovi is accelerating its growth through a 15M$ Series C investment led by TVM Capital Life Science

Ziad2022-11-25T14:03:39-05:00 Emovi announced today its partnership with TVM Capital Life Science and co-investors StandUp Ventures and Desjardins Capital to support its global commercial activities. This 15M$ Series C investment is combined with other capital for a total of 20M$. Read more >>